Baxalta (BXLT) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Baxalta Exceeds Guidance and Delivers Strong Sales and Earnings for First Quarter 2016
April 28, 2016 8:00 AM EDTPositive momentum continues across broad hematology and immunology portfolio Key pipeline and strategic achievements drive continued growth and unlock value across rare disease portfolio R&D and marketing investments position business for future success
BANNOCKBURN, Ill.--(BUSINESS WIRE)-- Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today reported strong first quarter 2016 financial results.
Baxaltas strong financial performance continues to highlight the... More
